Dawn Landolph, RN, BSN, OCN, MPA, provides an in-depth look at adagrasib for the treatment of patients with KRAS G12C-mutated, locally advanced or metastatic non-small cell lung cancer in a downloadable reference sheet.
Florida Cancer Specialists & Research Institute | Strategic Alliance Partners
Latest from Florida Cancer Specialists & Research Institute
Kristine Gibbons, RN, OCN, who is a Nurse Trainer at Florida Cancer Specialists & Research Institute, provides an in-depth look at elacestrant in a downloadable fact sheet.
Florida Cancer Specialists & Research Institute has experts who administer the latest and most advanced treatments for cancer available within the communities where their patients live.
Amanda Warner, MS, BSN, RN, OCN, who is manager of research informatics & real world evidence with Florida Cancer Specialists & Research Institute, provides an in-depth look at teclistamab in a downloadable fact sheet.
Patients with MPNs should be taught that ‘no symptom is too small to bring to the attention of your nurse.’
Physicians, clinicians and executive leaders of Florida Cancer Specialists & Research Institute, LLC (FCS) are joining industry experts from across the U.S. to envision the next 20 Years of Oncology Care.
A television commercial produced by Florida Cancer Specialists & Research Institute, LLC (FCS) has been recognized with a Silver ADDY® by the American Advertising Awards, which honors excellence in advertising as judged by creative industry professionals around the world.
Osheka Hansel, APRN, discusses the recent approval of futibatinib (Lytgobi) for patients with unresectable, locally advanced or metastatic intrahepatic FGFR2-positive cholangiocarcinoma.
Reducing ribociclib dosing by 200 mg or 400 mg did not affect overall survival in patients with hormone receptor–positive, HER2-negative, advanced breast cancer.
